GlassScriptPhysician profile
Peter J Kelley
NPI 1689630725
$997.64
in general payments reported to CMS, 2019-2025
18 companies · $910 in 2025
The $910 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.32 · 2024: $63.61 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $199.64 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $158.01 | 2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $116.98 | 2024-2025 | |
| Insulet Corporation | $87.80 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $67.02 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $66.19 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $47.01 | 2024-2025 | Voquezna |
| Cumberland Pharmaceuticals, INC. | $38.66 | 2025 | Kristalose |
| Axsome Therapeutics, INC. | $36.71 | 2025 | Auvelity |
| Corcept Therapeutics | $30.77 | 2025 | Korlym |
| Edwards Lifesciences Corporation | $26.81 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.32 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.08 | 2025 | Caplyta |
| Cranial Technologies, INC | $16.26 | 2025 | Doc Band |
| Merck Sharp & Dohme LLC | $16.06 | 2025 | Gardasil 9, Capvaxive |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $15.28 | 2025 | Flector, Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.04 | 2024 | Jardiance, Synjardy |
| Ars Pharmaceuticals Operations, INC. | $15.00 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.